Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Notes Payables (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Notes Payables for 11 consecutive years, with $400000.0 as the latest value for Q4 2025.

  • Quarterly Notes Payables changed N/A to $400000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $400000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $105000.0 for FY2023, N/A changed from the prior year.
  • Notes Payables hit $400000.0 in Q4 2025 for Vistagen Therapeutics, down from $658000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.0 million in Q2 2022 to a low of $105000.0 in Q1 2023.
  • Historically, Notes Payables has averaged $633387.5 across 3 years, with a median of $694000.0 in 2022.
  • Biggest YoY gain for Notes Payables was 24.44% in 2023; the steepest drop was 24.44% in 2023.
  • Year by year, Notes Payables stood at $419100.0 in 2022, then soared by 87.12% to $784200.0 in 2023, then plummeted by 48.99% to $400000.0 in 2025.
  • Business Quant data shows Notes Payables for VTGN at $400000.0 in Q4 2025, $658000.0 in Q3 2025, and $933000.0 in Q2 2025.